Skip to main content
NPCE logo

NPCE · NeuroPace Inc

Track NPCE — free
$8.43 +0.46 (+5.77%)
Market Cap
$274.58M
Shares
34.45M
Volume · Nov 17 155.2K Avg daily vol (3M) 246.14K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.97 Open$7.49 Day$7.05–8.18 52W close$7.56–19.29 Avg vol 30d372K Short int858K · 2.5% of shares · 8.5d Short vol47% Last earningsNov 12, 2026 DataApr 2021–Nov 2026 Filing10-Q · Nov 12

Up next

Mar 2, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 12
Earnings call
2026 revenue guidance cut after third-quarter shortfall

Neuropace cut 2026 revenue guidance to $91 million to $92 million from $99.5 million to $101.5 million after third-quarter revenue declined 1.1 percent to $23.1 million. It expects approximately 15% R&S revenue growth in 2027, excluding IGE expansion.

6 source passages
Neuropace's third quarter 2026 earnings conference call. Total revenue in the third quarter was $23.1 million, a decrease of 1.1 percent, compared with $23.4 million in the prior year period. We are revising full year total revenue guidance to $91 million to $92 million, compared with our previous range of $99.5 million to $101.5 million. Looking ahead, 2027 is shaping up to be another important year for NeuroPace, with multiple near-term potential catalysts across our clinical and product development programs, including remote care and IGE indication expansion. We will provide more detail on our outlook as we close out the year, but our current expectation is for our core R&S full-year revenue growth to be approximately 15%. Consistent with our approach to initial 2026 guidance, this outlook excludes any contribution from IGE indication expansion. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA says epilepsy expansion is not approvable in current form

NeuroPace said the FDA found its PMA-S for drug-resistant idiopathic generalized epilepsy not approvable in its current form. After meeting with the FDA, it is adding NAUTILUS data and context; nine-month revenue rose 11% to $67.9 million.

Revenue $23.1M ▼ 1.1% Net loss $3.3M Diluted EPS -$0.10
Read from the MD&A section
3 source passages
As disclosed on July 28, 2026, we received correspondence from the FDA notifying us that the PMA-S is not approvable in its current form and requesting additional information and further interactive communication. Based on the discussion with the FDA in the SIR meeting, we are amending our PMA-S with supplemental information, including additional data and context regarding the patient populations evaluated in the NAUTILUS clinical trial. Revenue increased by $6.8 million, or 11%, to $67.9 million for the nine months ended September 30, 2026, compared to $61.2 million for the nine months ended September 30, 2025. Open the document at this passage
Nov 12
Current report 8-K
2026 revenue guidance cut to $91 million to $92 million

NeuroPace reported third-quarter revenue of $23.1 million for the quarter ended September 30, 2026, saying results fell below expectations, and cut full-year 2026 revenue guidance to $91 million to $92 million.

Financial results
4 source passages
Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. Revises full year 2026 revenue guidance to $91 million to $92 million; focused on improving commercial execution and accelerating growth Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$102.61M
Trailing 12 months
Net income (TTM)
−$18.92M
Trailing 12 months
Revenue growth YoY
-1.1%
Year over year
Operating margin
-11.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-4.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$9.93M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.7%
Year over year · more shares
Price change (1Y)
-38.4%
Trailing year
Short interest
2.5%
Latest settlement · 8.5 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 12, 2026
Q3 FY26

TL;DR. Third-quarter RNS revenue grew only 1.4%, while 2026 revenue and adjusted EBITDA guidance were revised lower. Offsetting this, adjusted EBITDA improved to a $0.4 million gain, and management projects approximately 15% full-year RNS revenue growth in 2027 alongside IGE, Remote Care, Aurora and reimbursement catalysts.

Bullish
  • + Management expects approximately 15% full-year RNS revenue growth in 2027. new
  • + Adjusted EBITDA improved to a $0.4 million gain from a $1.3 million loss.
  • + The IGE PMA supplement could support potential FDA approval by mid-year 2027. new
  • + Remote Care was submitted to the FDA ahead of the previously communicated year-end timeline. new
  • + The Aurora real-world evidence study was initiated to support potential adolescent focal-epilepsy indication expansion. new
  • + A reimbursement increase for RNS replacement procedures is expected to provide an ongoing tailwind. new
Bearish
  • − Third-quarter RNS revenue grew only 1.4%. new
  • − Full-year 2026 revenue guidance was revised down to $91 million–$92 million from $99.5 million–$101.5 million. new
  • − Changes to sales leadership and field roles disrupted territories and affected results in certain accounts. new
  • − Customer concentration made disruptions at several large accounts disproportionately important to revenue. new
  • − Service revenue declined to $203,000 from $771,000 and more than offset RNS revenue growth. new
  • − Full-year adjusted EBITDA loss guidance was revised to $8.5 million–$9.5 million from $7.5 million–$8.5 million. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −46%
below
Price vs 50-day avg −39%
below
RSI (14) 24
oversold
MACD trend Negative
52-week position 3%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −38%
trailing
6-month return −53%
trailing
YTD return −48%
this year
Relative strength −52%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $13 › 200d $15 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.49% of shares out · ▼ -3.1% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
102 holders — mid 3-yr range
Squeeze score 63
elevated · 0–100
Fundamentals
Strong
Revenue growth +25%
Y/Y
Gross margin 77%
expanding
EPS growth +29%
Y/Y
Free cash flow $-11.3M
Balance sheet $37.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −61%
past year
ATR 14.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the Earnings Call filed Nov 12, 2026
full-year
Total revenue Lowered $91M – $92M
Aug 11, 2026 $99.5M – $101.5M changed to Nov 12, 2026 $91M – $92M
prior FY $99.99M midpoint −8.5% Y/Y
Full-year R&S revenue guidance Initiated 15%
full year
Service revenue Maintained $1M
Aug 11, 2026 $1M changed to Nov 12, 2026 $1M
R&S system revenue Initiated $90M – $91M
Full-year R&S revenue growth Initiated 10% – 11%
Adjusted operating expenses Non-GAAP Lowered $85M – $86M
Aug 11, 2026 $90M – $92M changed to Nov 12, 2026 $85M – $86M
Adjusted sales and marketing expense Non-GAAP Lowered $45M – $46M
Aug 11, 2026 $46M – $48M changed to Nov 12, 2026 $45M – $46M
Adjusted research and development expense Non-GAAP Lowered $25M
Aug 11, 2026 $27M changed to Nov 12, 2026 $25M
Adjusted general administrative expense Non-GAAP Initiated $15M
fourth quarter
Total revenue Initiated $23M – $24M
prior qtr $23.1M midpoint +1.7% QoQ
Underlying R&S growth Non-GAAP Initiated 5%
first half of 2027
R&S revenue growth Initiated 10% – 15%
Previous outlook earlier release · from the 8-K filed Aug 11, 2026

Still-open targets the latest release did not restate under the same label.

Non-GAAP gross margin · 2026 82% – 83%
GAAP gross margin · 2026 81.5% – 82.5%
Non-GAAP operating expenses · full year 2026 $90M – $92M
Prior guidance period ended · from the Earnings Call filed Aug 11, 2026
RNS revenue growth · Q3 2026 20%
Guided vs delivered · last 5 settled
Full year revenue full year 2025
guided $97M – $98M
$99.99M Beat +2.5%
Total revenue Full Year 2023
guided $62.5M – $63.5M
$65.42M Beat +3.8%
Total revenue 2022
guided $44.5M – $45.5M
$45.52M Beat +1.2%
Total revenue first quarter 2022
guided $10M – $11M
$11.37M Beat +8.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−46% Bearish
Price vs 50-day avg
−39% Bearish
RSI (14)
24 Neutral
MACD trend
Negative Bearish
52-week position
3% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $13 › 200d $15 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +14 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.49% of shares out · ▼ -3.1% MoM · 8.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
102 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $8 Now $8 · 3% Range high $19
vs 200-day avg -46% vs 50-day avg -39%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA from continuing operations (Non-GAAP) non-GAAP -6.04M Six Months Ended June 30, 2026 —
Non-GAAP cost of goods sold non-GAAP 7.65M Six Months Ended June 30, 2026 —
Non-GAAP general and administrative expense non-GAAP 8.14M Six Months Ended June 30, 2026 —
Non-GAAP gross margin non-GAAP 83.4% Q2 2026 —
Non-GAAP loss from continuing operations non-GAAP -6.17M Six Months Ended June 30, 2026 —
Non-GAAP loss from operations non-GAAP -$2.8M Q2 2026 —
Non-GAAP net loss non-GAAP -$3.9M Q2 2026 —
Non-GAAP net loss from continuing operations non-GAAP -8.35M Six Months Ended June 30, 2026 —
Non-GAAP operating expenses non-GAAP 43.35M Six Months Ended June 30, 2026 —
Non-GAAP research and development expense non-GAAP 12.75M Six Months Ended June 30, 2026 —
Non-GAAP sales and marketing expense non-GAAP 22.46M Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NPCE
NeuroPace Inc
this stock
$274.58M -48.4% +25.1% — 2.5%
ABT
Abbott Laboratories
$186.10B -14.2% +5.7% 40.1 1.1%
MDT
Medtronic plc
$131.60B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$118.29B -11.6% +11.2% 33.1 1.7%
BSX
Boston Scientific Corp
$63.33B -54.2% +12.5% 18.5 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
102
% held
76.9%
Net QoQ
-93.1K sh
Top holder
First Light Asset Managem…
Held Float
View
Held by Funds
Fund positions
113
View
Short & Settlement
Short Interest Falling
Shares short
858.3K
Days to cover
8.5d
Change
-27.9K sh
View
Short Volume
Short vol %
47%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
531
Value
$7.5K
As of
Sep 18, 2026
View
Off-Exchange
Off-exchange %
31.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$100.0M
Net income (FY)
$-21.5M
EPS diluted
$-0.66
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 12, 2026
This year
16

NeuroPace reported third-quarter revenue of $23.1 million for the quarter ended September 30, 2026, saying results fell below expectations, and cut full-year 2026 revenue guidance to $91 million to $92 million.

View
Proposed Sales
Value
$404.8K
Shares
25.0K
Filed
Dec 15, 2025
View
Exempt Offerings
Offering
$96.4M
Filed
Aug 31, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
NeuroPace Reports Third Quarter 2…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
NPCE -39.3% -37.6% -53.3% -35.2% -48.4%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -37.6% -34.1% -51.9% -33.1% -56.9%
Key facts CIK 1528287 CUSIP 641288105 13F (30d) 115 filings 100 filers Visit website Investor relations